
Marco Galardini appointed W2 professor at TWINCORE
Inaugural lecture on 6 March 2026

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

Inaugural lecture on 6 March 2026

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Waqas F, S da Costa L, Zapatero-Belinchón F, Carter-Timofte M, Lasswitz L, van der Horst D, Möller R, Dahlmann J, Olmer R, Geffers R, Gerold G, Olagnier D, Pessler F
Elwy A, Abdelrahman H, Specht J, Ewert G, Friebus-Kardash J, Dhiman S, Falkenstein J, Christ T, Wiebeck E, Shamoon A, Leimkühler N, Gramberg T, Russ A, Kalinke U, Kuang F, Sutter K, Kopf M, Mack M, Hansen W, Nimmerjahn F, Lang K
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
Thanks to high-throughput sequencing, genome sequences of hundreds of bacterial strains can be analyzed efficiently, revealing differences of up to 60 % in gene content, as in E. coli. With the help of machine learning, we want to better predict the functions of accessory genes and decipher their contribution to survival in specialized niches.
Prof. Makoto Takeda
Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Japan
“Host protease-mediated activation of respiratory viruses: From the laboratory bench to the frontlines of infectious disease control”
Postponed - new date will be announced soon.

